Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Revenue Recognition and Contractual Adjustments (Tables)

v3.10.0.1
Revenue Recognition and Contractual Adjustments (Tables)
6 Months Ended
Jun. 30, 2018
Revenue Recognition [Abstract]  
Summary of Contract Assets and Liabilities
The following table summarizes the values of contract assets, capitalized commissions and contract liabilities as of June 30, 2018 and December 31, 2017 (in thousands):
 
June 30, 2018
 
December 31, 2017
Current pharma contract asset
$
400

 
$
541

Long-term pharma contract asset
29

 
31

Total pharma contract asset
$
429

 
$
572

 
 
 
 
Current pharma capitalized commissions
$
264

 
$
371

Long-term pharma capitalized commissions
574

 
171

Total pharma capitalized commissions
$
838

 
$
542

 
 
 
 
Current pharma contract liability
$
2,155

 
$
1,406

Long-term pharma contract liability
648

 
283

Total pharma contract liability
$
2,803

 
$
1,689

Summary of Disaggregation of Revenue
The following table details the disaggregation of revenue for both the Clinical and Pharma Services Segments (in thousands):
 
 
Three Months Ended June 30,
 
Six Months Ended June 30,
 
 
2018
 
2017
 
2018
 
2017
Clinical Services:
 
 
 
 
 
 
 
 
    Client direct billing
 
$
40,847

 
$
36,796

 
$
79,561

 
$
70,427

    Commercial Insurance
 
8,981

 
10,124

 
18,922

 
21,560

    Medicare and Medicaid
 
9,024

 
8,403

 
17,201

 
16,221

    Self-Pay
 
688

 
224

 
827

 
247

Total Clinical Services
 
$
59,540

 
$
55,547

 
$
116,511

 
$
108,455

Pharma Services:
 
8,206

 
6,717

 
14,658

 
11,238

Total Revenue
 
$
67,746

 
$
62,264

 
$
131,169

 
$
119,693